

Clinical trials of canagliflozin

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
canagliflozin vs placebo			
CANVAS , 2017 [NCT01032629] n=5795/4347 follow-up: 188.2 weeks (mean)	canagliflozin versus placebo	participants with type 2 diabetes and high cardiovascular risk	double-blind
3005: monotherapy <i>ongoing</i> n=NA follow-up: 26 weeks	-	-	
canagliflozin vs placebo (add-on MET)			
CANTATA-D <i>ongoing</i> [NCT01106677] n=NA follow-up: 26 weeks	-	-	
3009: Add-on to MET <i>ongoing</i> n=NA follow-up: 52 weeks	-	-	
3008: Add-on to insulin <i>ongoing</i> n=NA follow-up: 18 weeks	-	-	
canagliflozin vs placebo (add-on MET+SU)			
3015: Add-on to MET + SU <i>ongoing</i> n=NA follow-up: 52 weeks	-	-	
3002: Add-on to MET + SU <i>ongoing</i> n=NA follow-up: 26 weeks	-	-	

continued...

Trial	Treatments	Patients	Trials design and methods
canagliflozin vs placebo (add-on MET+TZD)			
3012: Add-on to MET +TZD <i>ongoing</i> n=NA follow-up: 26 weeks	-	-	
canagliflozin vs placebo (add-on SU)			
3008: Add-on to SU <i>ongoing</i> n=NA follow-up: 18 weeks	-	-	

More details and results :

- SGLT2 inhibitors for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q479>
- glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q576>

References

CANVAS, 2017:

Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, Desai M, Shaw W, Jiang J, Vercruysse F, Meininger G, Matthews D Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—a randomized placebo-controlled trial. *Am Heart J* 2013;166:217-223.e11 [23895803]

Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Weiss R, Rosenstock J, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G, Neal B Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. *Diabetes Ther* 2015;6:289-302 [26081793]

Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, Desai M, Shaw W, Capuano G, Alba M, Jiang J, Vercruysse F, Meininger G, Matthews D Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. *Diabetes Care* 2015;38:403-11 [25468945]

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erond N, Shaw W, Law G, Desai M, Matthews DR Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med* 2017;: [28605608]

3005: monotherapy, 0:

ongoing trial

CANTATA-D, 0:

ongoing trial NCT01106677

3009: Add-on to MET, 0:

ongoing trial

3008: Add-on to insulin, 0:

ongoing trial

3015: Add-on to MET + SU, 0:

ongoing trial

3002: Add-on to MET + SU, 0:

ongoing trial

3012: Add-on to MET +TZD, 0:

ongoing trial

3008: Add-on to SU, 0:

ongoing trial

2 diabetic kidney disease

Trial	Treatments	Patients	Trials design and methods
canagliflozin vs placebo			
CREDESCENCE <i>ongoing</i> [NCT02065791] n=4200 follow-up: 66 months	Canagliflozin 100 mg over-encapsulated tablet orally once daily versus placebo	with type 2 diabetes mellitus, Stage 2 or 3 chronic kidney disease and macroalbuminuria, who are receiving standard of care including a maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker	Parallel groups double-blind

More details and results :

- All mechanism for diabetic kidney disease in all type of patients at <http://www.trialresultscenter.org/go-Q667>

References

CREDESCENCE, 0:

ongoing trial NCT02065791

Entry terms: Invokana,